Volume 24 Issue 3
Mar.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(3): 390-394
HU Yiyang, YAO Liuxu, LI Weiwei, HE Liu, LI Yuhong. Identification of HTR1D as a therapeutic target and prognostic indicator for colorectal cancer[J]. Chinese Journal of General Practice, 2026, 24(3): 390-394. doi: 10.16766/j.cnki.issn.1674-4152.004403
Citation: HU Yiyang, YAO Liuxu, LI Weiwei, HE Liu, LI Yuhong. Identification of HTR1D as a therapeutic target and prognostic indicator for colorectal cancer[J]. Chinese Journal of General Practice, 2026, 24(3): 390-394. doi: 10.16766/j.cnki.issn.1674-4152.004403
shu

Identification of HTR1D as a therapeutic target and prognostic indicator for colorectal cancer

doi: 10.16766/j.cnki.issn.1674-4152.004403
  • 1.

    Center for Rehabilitation Medicine, Department of Anesthesiology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China

Funds:

 2024KY680

  • Received Date: 2025-03-16
    Available Online: 2026-06-02
    Abstract
  •   Objective  To screen and identify differential genes in colorectal cancer by bioinformatics, and to explore the role and value of 5-hydroxytryptamine receptor 1D (5-HTR1D) in colorectal cancer.  Methods  The differentially expressed genes (DEGs) between colorectal cancer and adjacent normal tissues were identified in this study by using GEO data set. Subsequently, a protein-protein interaction network and key genes related to colorectal cancer were established. Tissue samples from colorectal cancer and adjacent tissues were collected for immunohistochemistry, and different colorectal cancer cell lines were subjected to Western blotting to verify the differences of HTR1D. The potential mechanism of HTR1D was discussed by GO and KEGG enrichment analysis. Kaplan-Meier survival analysis and multivariate Cox regression analysis were used to verify the correlation between HTR1D expression and the clinicopathological features and prognosis of patients with colorectal cancer. A mouse xenotransplantation model was established, and the effectiveness of HTR1D as a target for CRC treatment was verified by in vivo experiments.  Results  The results of the present study demonstrated that the expression of HTR1D was considerably upregulated in CRC tissue, and was principally expressed in the cytoplasm of tumor cells. Western blotting assay was performed to detect HTR1D expression in CRC cell lines: HTR1D was highly expressed in poorly differentiated cell lines. From clinical aspects, HTR1D expression was significantly correlated with tumor size (P=0.044)and hypertension(P=0.039) in CRC. Kaplan-Meier survival analysis [(18.9±2.5) mouths vs. (26.7±1.9) mouths, P=0.033] and multivariate Cox regression analysis indicated that the expression of HTR1D was closely associated with the prognosis of patients (P=0.019, HR=1.159, 95% CI: 1.024-1.312). In vivo experiments demonstrate that the inhibition of HTR1D expression results in a reduction of expression level in a reduction in the mass and volume of tumors.  Conclusion  HTR1D has been identified as both a viable therapeutic target and a prognostic indicator in colorectal cancer cases.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    FILHO A M, LAVERSANNE M, FERLAY J, et al. The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide[J]. Int J Cancer, 2025, 156(7): 1336-1346. doi: 10.1002/ijc.35278
    [2]
    张丽, 凌晨, 沈轶骊. 血清microRNA-21、microRNA-193a-3p表达与结直肠癌患者手术预后的关系[J]. 中国现代医学杂志, 2024, 34(5): 1-6.

    ZHANG L, LING C, SHEN Y L. The relationship of preoperative serum microRNA-21, microRNA-193a-3p levels with postoperative prognosis of colorectal cancer patients[J]. China Journal of Modern Medicine, 2024, 34(5): 1-6.
    [3]
    CAO J L, YANG X, CHEN S Y, et al. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: a meta-analysis and bioinformatics analysis[J]. Transl Oncol, 2022, 20: 101375. DOI: 10.1016/j.tranon.2022.101375.
    [4]
    SINGH D, SINGH P, SRIVASTAVA P, et al. Development and challenges in the discovery of 5-HT1A and 5-HT7 receptor ligands[J]. Bioorg Chem, 2023, 131: 106254. DOI: 10.1016/j.bioorg.2022.
    [5]
    ZHANG Y Y, MAO M H, HAN Z X. Identification of a gene prognostic signature for oral squamous cell carcinoma by RNA sequencing and bioinformatics[J]. Biomed Res Int, 2021: 6657767. DOI: 10.1155/2021/6657767.
    [6]
    曾薇, 唐菊彬, 陈向宙, 等. 基于癌症免疫周期筛选结直肠癌免疫联合治疗的新靶点[J]. 中华全科医学, 2025, 23(1): 31-35, 147. doi: 10.16766/j.cnki.issn.1674-4152.003829

    ZENG W, TANG J B, CHEN X Z, et al. Screening novel targets for combination immunotherapy of colorectal cancer based on cancer immune cycle[J]. Chinese Journal of General Practice, 2025, 23(1): 31-35, 147. doi: 10.16766/j.cnki.issn.1674-4152.003829
    [7]
    MURPHY C C, ZAKI T A. Changing epidemiology of colorectal cancer: birth cohort effects and emerging risk factors[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(1): 25-34. doi: 10.1038/s41575-023-00841-9
    [8]
    JIANG C, ZHOU Q J, YI K, et al. Colorectal cancer initiation: understanding early-stage disease for intervention[J]. Cancer Lett, 2024, 589: 216831. DOI: 10.1016/j.canlet.2024.216831.
    [9]
    ZHANG J L, CHEN B N, LI H, et al. Cancer-associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2-IGF1R and Hippo-YAP1 signaling pathways[J]. J Pathol, 2023, 259(2): 205-219. doi: 10.1002/path.6033
    [10]
    PENG D D, FU M Y, WANG M N, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Mol Cancer, 2022, 21(1): 104. DOI: 10.1186/s12943-022-01569-x.
    [11]
    MELLMAN I, CHEN D S, POWLES T, et al. The cancer-immunity cycle: indication, genotype, and immunotype[J]. Immunity, 2023, 56(10): 2188-2205. doi: 10.1016/j.immuni.2023.09.011
    [12]
    ZHANG Y E, STUELTEN C H. Alternative splicing in EMT and TGF-β signaling during cancer progression[J]. Semin Cancer Biol, 2024, 101: 1-11.
    [13]
    边晓倩, 王莎莎, 赵淑芬, 等. Ⅲ期结直肠癌血清细胞因子水平与术后短期复发关系[J]. 青岛大学学报(医学版), 2024, 60(1): 72-76.

    BIAN X Q, WANG S S, ZHAO S F, et al. Association between serum cytokine levels and postoperative short-term recurrence in patients with stageⅢcolorectal cancer[J]. Journal of Qingdao University(Medical Sciences), 2024, 60(1): 72-76.
    [14]
    KHARE T, BISSONNETTE M, KHARE S. CXCL12-CXCR4/CXCR7 axis in colorectal cancer: therapeutic target in preclinical and clinical studies[J]. Int J Mol Sci, 2021, 22(14): 7371. DOI: 10.3390/ijms22147371.
    [15]
    DENK D, RAMAKRIISHAN M, CONCHE C, et al. IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis[J]. Immunity, 2025, 58(3): 701-715. e8. doi: 10.1016/j.immuni.2025.02.005
    [16]
    BALAKRISHNA P, GEORGE S, HATOUM H, et al. Serotonin pathway in cancer[J]. Int J Mol Sci, 2021, 22(3): 1268. DOI: 10.3390/ijms22031268.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (14) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return